News FAMHP

There are 25 result(s) found based on your search criteria

11-20 from 25 result(s)

Coronavirus - Derogation for COVID-19 clinical trials of medicinal products containing or consisting of genetically modified organisms

In the context of the COVID-19 crisis, the European Union adopted a regulation providing for a temporary derogation from European legislation on genetically modified organisms.

Coronavirus: the FAMHP is allowing an extension of the payment deadlines expiring before 01.07.2020.

In the context of the coronavirus crisis, the FAMHP is extending all payment periods expiring before 01.07.2020 for all its customers.

Coronavirus: third version of the Alternative Test Protocol (ATP) for surgical face masks

The FAMHP is keeping a close eye on the situation on the ground. Consequently, the Alternative Test Protocol (ATP) is being adapted. From now on, it will no longer be possible to sell surgical masks which do not comply with the ATP as comfort masks. One of the parameters has also been refined based on an evaluation of the new test results. Furthermore, masks that have been subject to the ATP must carry a warning on the packaging. The third version of the ATP is applicable from 04.06.2020.

Coronavirus: updated guidelines for verifying the compliance and suitability of surgical face masks

The FAMHP has issued guidelines for checking the compliance and suitability of surgical face masks during the COVID-19 crisis. The guidelines are intended for companies, institutions and authorities that order, sell or use these masks.

Coronavirus: relaxation of paracetamol measures for pharmacists and patients

Sales of paracetamol remain stable, which is why the restriction of only one box per patient is being lifted. The quotas for pharmaceutical companies and wholesalers have already been abolished. Only the intravenous form remains subject to restriction.

Web portal - updates to the “My company” and “My activities” applications

In anticipation of the European regulations on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), the FAMHP has updated the “My company” and “My activities” applications in its web portal.

Coronavirus: how should tests be made available in Belgium?

Belgian manufacturers of COVID-19 tests for professional use and Belgian authorised representatives of foreign manufacturers must notify the FAMHP when placing their tests on the market. This notification does not constitute an offer of equipment to the Belgian state. Companies wishing to offer tests to the government must contact the FPS Public Health.

Coronavirus: new version of Alternative Test Protocol (ATP) for surgical face masks

An Alternative Test Protocol (ATP) has been developed for surgical face masks that do not have the necessary declarations, certificates and test reports. In the event of a positive result, this protocol still allows them to be used as a surgical mask or comfort mask. Test results are now also made public.

International non-proprietary name (INN) prescriptions: version 8 of the “Operational rules for INN prescriptions in medical and pharmaceutical practice and in the electronic medical record”

The FAMHP's evaluators have finalised version 8 of the note “International non-proprietary name prescriptions – Operational rules for INN prescriptions in medical and pharmaceutical practice and in the electronic medical record”.

Coronavirus: Belgian guideline for the management of clinical trials during the coronavirus pandemic

A national guideline is available to complement European guidelines for the management of clinical trials during the coronavirus pandemic.

11-20 from 25 result(s)